MIST — Milestone Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00- $70.04m
- $53.70m
Annual balance sheet for Milestone Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 142 | 114 | 64.6 | 66 | 69.7 |
| Net Total Receivables | 0.948 | 0.483 | 1.21 | 3.85 | 2.39 |
| Prepaid Expenses | |||||
| Total Current Assets | 149 | 119 | 71.8 | 73 | 73.9 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.29 | 0.926 | 2.68 | 2.19 | 1.57 |
| Total Assets | 150 | 120 | 74.5 | 75.2 | 75.5 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 6.16 | 6.78 | 6.14 | 7.23 | 8.13 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6.86 | 7.25 | 8.13 | 58.5 | 62.4 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 143 | 113 | 66.3 | 16.8 | 13.1 |
| Total Liabilities & Shareholders' Equity | 150 | 120 | 74.5 | 75.2 | 75.5 |
| Total Common Shares Outstanding |